View in EDS

Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.

Saved in:
Bibliographic Details
Title: Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma.
Authors: Wei BR; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.; Leidos Biomedical Research, Inc., Frederick, Maryland., Hoover SB; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Peer CJ; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Dwyer JE; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Adissu HA; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Shankarappa P; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Yang H; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Lee M; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Peat TJ; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Figg WD; Clinical Pharmacology Program and the Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland., Simpson RM; Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. ms43b@nih.gov.
Source: Molecular cancer therapeutics [Mol Cancer Ther] 2020 Nov; Vol. 19 (11), pp. 2308-2318. Date of Electronic Publication: 2020 Sep 17.
Publication Type: Journal Article; Research Support, N.I.H., Intramural
Journal Info: Publisher: American Association for Cancer Research, Inc Country of Publication: United States NLM ID: 101132535 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-8514 (Electronic) Linking ISSN: 15357163 NLM ISO Abbreviation: Mol Cancer Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1538-8514
DOI:10.1158/1535-7163.MCT-19-0858